2024
Barriers to and facilitators of improving physical activity and nutrition behaviors during chemotherapy for breast cancer: a sequential mixed methods study
Puklin L, Irwin M, Sanft T, Ferrucci L, Harrigan M, McGowan C, Cartmel B, Zupa M, Winer E, Deyling M, Ligibel J, Basen-Engquist K, Spiegelman D, Sharifi M. Barriers to and facilitators of improving physical activity and nutrition behaviors during chemotherapy for breast cancer: a sequential mixed methods study. Supportive Care In Cancer 2024, 32: 590. PMID: 39141176, DOI: 10.1007/s00520-024-08789-5.Peer-Reviewed Original ResearchConceptsPhysical activityLifestyle interventionSelf-reported PA questionnaireSelf-reported diet qualityBreast cancerHealthy Eating Index-2015Stage I-III breast cancerBenefits of PASequential mixed methods studyI-III breast cancerChemotherapy-related symptomsMixed methods studyThematic content analysisBehavioral goalsSense of controlBody mass indexPA questionnaireSemi-structured interviewsMean body mass indexTranscribed verbatimIntervention armTailored educationDiet qualityNutritional behaviorMental benefitsImproving lifestyle behaviors during chemotherapy for breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial
Puklin L, Ferrucci L, Harrigan M, McGowan C, Zupa M, Cartmel B, Li F, Ligibel J, Spiegelman D, Sharifi M, Sanft T, Irwin M. Improving lifestyle behaviors during chemotherapy for breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial. Cancer 2024, 130: 2440-2452. PMID: 38470431, PMCID: PMC11214600, DOI: 10.1002/cncr.35280.Peer-Reviewed Original ResearchPhysical activityDiet qualityHEI-2015Strength trainingLifestyle behaviorsHealthy Eating Index (HEI)-2015Breast cancerAssociated with baseline fatigueImprove physical activityImprove lifestyle behaviorsHigher HEI-2015Associated with higher oddsExercise interventionUsual careIntervention armIntervention groupBaseline fatigueLifestyle interventionYearlong interventionLower fatigueHigher oddsSecondary analysisLogistic regressionNewly diagnosed patientsStudy arms
2023
Post-diagnosis weight trajectories and mortality among women with breast cancer
Puklin L, Li F, Cartmel B, Zhao J, Sanft T, Lisevick A, Winer E, Lustberg M, Spiegelman D, Sharifi M, Irwin M, Ferrucci L. Post-diagnosis weight trajectories and mortality among women with breast cancer. Npj Breast Cancer 2023, 9: 98. PMID: 38042922, PMCID: PMC10693588, DOI: 10.1038/s41523-023-00603-5.Peer-Reviewed Original ResearchBody mass indexBreast cancer diagnosisWeight changeCause mortalityClinical characteristicsWeight gainWeight lossBreast cancerWeight trajectoriesPost-diagnosis weight changeBreast cancer-specific mortalityCox proportional hazards modelModern treatment eraCancer-specific mortalityCancer diagnosisModerate weight lossModerate weight gainProportional hazards modelAdverse health outcomesElectronic health recordsTreatment eraBaseline characteristicsTumor RegistryMass indexWeight managementA qualitative study on the role of financial toxicity on adoption of healthy lifestyle behavior after breast cancer among Black and Latina women.
Nsubayi C, Pichardo M, Ginader A, Peña K, Nguyen T, Irwin M, Sanft T, Fayanju O, Molina Y. A qualitative study on the role of financial toxicity on adoption of healthy lifestyle behavior after breast cancer among Black and Latina women. JCO Oncology Practice 2023, 19: 273-273. DOI: 10.1200/op.2023.19.11_suppl.273.Peer-Reviewed Original ResearchLocal organizationsBreast cancer survivorsQualitative interview dataLatina breast cancer survivorsLatina womenLifestyle behavior changeHousing insecuritySocial workersCancer survivorsInstitutional levelLevel of accessInterview dataIdentified strategiesFinancial toxicityInterpersonal levelCommunity levelFinancial resourcesQualitative studyBreast cancerInductive approachContent analysisTypes of resourcesFinancial hardshipThematic categoriesBehavior changeRandomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study
Sanft T, Harrigan M, McGowan C, Cartmel B, Zupa M, Li F, Ferrucci L, Puklin L, Cao A, Nguyen T, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf T, Chagpar A, Silber A, Tanasijevic A, Ligibel J, Irwin M. Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study. Journal Of Clinical Oncology 2023, 41: 5285-5295. PMID: 37656930, PMCID: PMC10691793, DOI: 10.1200/jco.23.00871.Peer-Reviewed Original ResearchConceptsRelative dose intensityPathologic complete responseProportion of patientsBreast cancerNeoadjuvant chemotherapyChemotherapy completionComplete responseNutrition interventionsHigher pathologic complete responseHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Triple-negative breast cancerChemotherapy dose adjustmentsHome-based exerciseGrowth factor receptor 2Breast cancer outcomesEffects of exerciseFactor receptor 2Electronic medical recordsChi-square testUsual careDose intensityExercise interventionDose adjustmentRandomized trialsPersistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
Foldi J, Tsagianni A, Salganik M, Schnabel C, Brufsky A, van Londen G, Pusztai L, Sanft T. Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer. BMC Cancer 2023, 23: 606. PMID: 37391697, PMCID: PMC10314405, DOI: 10.1186/s12885-023-11104-w.Peer-Reviewed Original ResearchConceptsAdjuvant endocrine therapyEarly-stage hormone receptor-positive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerEndocrine therapyBreast cancerLate breast cancer recurrenceExtended endocrine therapyNon-persistence ratesIntolerable side effectsBone density scanBreast cancer recurrenceHigher likelihoodRate of persistenceElectronic health recordsConclusionsIn patientsMedication persistenceTreatment persistenceLow patientsMetastatic recurrenceCancer recurrenceCommon reasonSide effectsPatientsStage IOral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
Shatsky R, Thomas A, Yau C, Chien A, Falkson C, Stringer-Reasor E, Omene C, Trivedi M, Boughey J, Sanford A, Arora M, Sanft T, Nanda R, Isaacs C, Brown T, Hylton N, DeMichele A, Yee D, Esserman L. Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL. Journal Of Clinical Oncology 2023, 41: lba612-lba612. DOI: 10.1200/jco.2023.41.17_suppl.lba612.Peer-Reviewed Original ResearchImmune related adverse eventsWeeks x 4High-risk breast cancerPD-1 inhibitorsPathologic complete responseOral paclitaxelPeripheral neuropathyControl armBreast cancerRates of neutropeniaEfficacy of immunotherapyPhase 2 trialRelated adverse eventsHigh-risk cancerBiomarker subtypesI-SPY2Neoadjuvant agentWeekly trastuzumabOral agentsPrimary endpointAdverse eventsComplete responseOral combinationCombination therapyPump inhibitorsA review of the impact of energy balance on triple-negative breast cancer
Akingbesote N, Owusu D, Liu R, Cartmel B, Ferrucci L, Zupa M, Lustberg M, Sanft T, Blenman K, Irwin M, Perry R. A review of the impact of energy balance on triple-negative breast cancer. JNCI Monographs 2023, 2023: 104-124. PMID: 37139977, DOI: 10.1093/jncimonographs/lgad011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTriple-negative breast cancerInterventional studyBreast cancerCancer treatmentClinical interventional studyClinical observationalImmune activationCancer outcomesCancer careClinical studiesOverall healthEnergy intakeNarrative reviewCancer cellsEnergy expenditureCancerTreatmentEnergy balanceOutcomesExerciseReviewDetrimental effectsImmunotherapyStudyIntakeDiet and physical activity interventions in Black and Latina women with breast cancer: A scoping review
Pichardo M, Sanft T, Ferrucci L, Romero-Ramos Y, Cartmel B, Harrigan M, Velazquez A, Fayanju O, Winer E, Irwin M. Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review. Frontiers In Oncology 2023, 13: 1079293. PMID: 36994212, PMCID: PMC10040823, DOI: 10.3389/fonc.2023.1079293.Peer-Reviewed Original ResearchBreast cancer survivorsPhysical activity interventionsLifestyle interventionCancer survivorsActivity interventionsLatina womenEfficacy trialsBreast cancerLatina breast cancer survivorsTrial of dietOne-year followFavorable behavioral changesBreast cancer diagnosisPrimary outcomeAvailable peer-reviewed literatureFuture trialsInformal care giversPilot trialSustained behavior changeEfficacy studiesHealthful lifestyleCare giversTrialsWeight lossCancer diagnosisA qualitative study of sleep in young breast cancer survivors: “No longer able to sleep through the night”
Hwang Y, Conley S, Redeker N, Sanft T, Knobf M. A qualitative study of sleep in young breast cancer survivors: “No longer able to sleep through the night”. Journal Of Cancer Survivorship 2023, 18: 828-835. PMID: 36680672, DOI: 10.1007/s11764-023-01330-3.Peer-Reviewed Original ResearchSleep healthAnxiety/worryBreast cancer survivorsEveryday life stressorsSleep disturbancesYoung breast cancer survivorsCancer survivorsLongitudinal designYears of survivorshipLife stressorsExperience difficultiesPsychological symptomsSequential mixed-methods studySemi-structured interviewsRuminating thoughtsInterpretive description approachStudy phaseVasomotor symptomsGreater symptom distressSleep changesBreast cancerMixed-methods studySleep qualityFuture researchDisturbed sleepA qualitative study identifying challenges resulting from complex evidence on lifestyle factors and cancer: perspectives from Black and Latina cancer survivors and healthcare providers
Pichardo M, Irwin M, Sanft T, Ferrucci L, Ginader A, Nguyen T, Esserman D, Cartmel B, Molina Y. A qualitative study identifying challenges resulting from complex evidence on lifestyle factors and cancer: perspectives from Black and Latina cancer survivors and healthcare providers. Supportive Care In Cancer 2023, 31: 111. PMID: 36633678, PMCID: PMC9912693, DOI: 10.1007/s00520-022-07539-9.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsOncology healthcare providersCancer survivorsLifestyle behaviorsHealthcare providersGeneric messagingEvidence-based knowledgeFemale breast cancer survivorsHealthcare provider counselingHealthy lifestyle guidelinesPatient-level barriersHealthy lifestyle behaviorsLifestyle guidelinesProvider counselingLifestyle factorsOncology careCancer outcomesBreast cancerConsistency of evidenceCurrent evidenceAvailable evidenceSurvivorsCancer diagnosisLevel barriersCancer
2022
Factors associated with sleep health in young women after breast cancer treatment
Hwang Y, Conley S, Jeon S, Redeker N, Sanft T, Knobf M. Factors associated with sleep health in young women after breast cancer treatment. Research In Nursing & Health 2022, 45: 680-692. PMID: 36102624, DOI: 10.1002/nur.22264.Peer-Reviewed Original ResearchConceptsPoor sleep healthSleep healthCognitive appraisalPittsburgh Sleep Quality IndexWorse family functioningBreast cancerPsychological symptom distressYoung womenContext of familyFamily functioningDiverse cancer survivorsRoutine survivorship carePsychosocial variablesCross-sectional designMediation effectSleep Quality IndexSleep health disparitiesBreast cancer treatmentSignificant clinical problemPsychosocial factorsNon-Hispanic whitesHalf of participantsSurvivorship careCancer survivorsMean ageRandomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study.
Sanft T, Harrigan M, Cartmel B, Li F, Zupa M, McGowan C, Ferrucci L, Puklin L, Nguyen T, Tanasijevic A, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf M, Chagpar A, Silber A, Ligibel J, Irwin M. Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study. Journal Of Clinical Oncology 2022, 40: 12007-12007. DOI: 10.1200/jco.2022.40.16_suppl.12007.Peer-Reviewed Original ResearchRelative dose intensityHigh relative dose intensityBreast cancerDose-response effectPhysical activityPA interventionsNeoadjuvant chemotherapyChemotherapy completionDiet qualityStage I breast cancerEndocrine therapy adherenceTrial of dietDifferent chemotherapy regimensI breast cancerBody mass indexPatient-reported outcomesHealthy Eating IndexBetter diet qualityHigh physical activityMore physical activityElectronic medical recordsChi-square testUC participantsChemotherapy regimensSecondary endpoints0590 Factors Associated with Sleep Health in Young Women After Breast Cancer Treatment
Hwang Y, Conley S, Jeon S, Redeker N, Sanft T, Knobf M. 0590 Factors Associated with Sleep Health in Young Women After Breast Cancer Treatment. Sleep 2022, 45: a259-a260. DOI: 10.1093/sleep/zsac079.587.Peer-Reviewed Original ResearchPittsburgh Sleep Quality IndexPoor sleep healthSleep healthBreast cancerPsychosocial dataGlobal Pittsburgh Sleep Quality IndexYoung womenCancer treatmentRoutine survivorship careSevere night sweatsSleep Quality IndexBreast cancer treatmentCross-sectional studyPrimary cancer treatmentSignificant clinical problemYears of ageQuality of lifeNon-Hispanic whitesWarrants further investigationEndocrine therapyGeneral Functioning subscaleNight sweatsSurvivorship careClinical factorsCancer survivors
2021
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors.
Dieli-Conwright C, Harrigan M, Cartmel B, Chagpar A, Bai Y, Rimm D, Pusztai L, Lu L, Sanft T, Irwin M. Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. Journal Of Clinical Oncology 2021, 39: e12501-e12501. DOI: 10.1200/jco.2021.39.15_suppl.e12501.Peer-Reviewed Original ResearchBreast cancer survivorsWeight loss interventionSerum insulin levelsCancer survivorsLoss interventionPercent body fatSerum levelsSerum biomarkersTissue biomarkersBody compositionMonth 6Insulin levelsBreast tissueBreast cancerInsulin receptorBody fatStage I breast cancerBreast tissue levelsI breast cancerWeight loss trialBreast tissue markersLevels of CD163Breast tissue biopsiesUsual careLifestyle interventionHow did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh riskAbstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Beckwith H, Schwab R, Yau C, Stringer-Reasor E, Wei S, Chien A, Albain K, Kalinsky K, Wallace A, Elias A, Yee D, Clark A, Boughey J, Han H, Nanda R, Isaacs C, Mitri Z, Lang J, Thomas A, Sanft T, DeMichele A, Perlmutter J, Rugo H, Hylton N, Symmans W, Melisko M, van't Veer L, Wilson A, Asare S, Sanil A, Berry D, Esserman L. Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research 2021, 81: pd1-10-pd1-10. DOI: 10.1158/1538-7445.sabcs20-pd1-10.Peer-Reviewed Original ResearchStage II/III breast cancerWeekly x 4I-SPY 2 TRIALI-SPY 2PCR rateBreast cancerI-SPYPeripheral neuropathyHigh-risk stage II/III breast cancerTumor samplesRates of peripheral neuropathyControl armEvaluate novel agentsPathological complete responsePhase 2 trialTreatment of angiosarcomaModerate to high expressionSide effect profileTime of surgeryBayesian predictive probability of successBreast tumor samplesAntibody drug conjugatesHR-HER2Complete responseNeoadjuvant therapy
2020
Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers.
Foldi J, Schnabel C, Salganik M, Pusztai L, Sanft T. Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers. Journal Of Clinical Oncology 2020, 38: 527-527. DOI: 10.1200/jco.2020.38.15_suppl.527.Peer-Reviewed Original ResearchLate distant recurrenceAdjuvant endocrine therapyEndocrine therapyDistant recurrenceDXA scansBreast cancerHigh riskStage IEarly-stage hormone receptorExtended endocrine therapyIntolerable side effectsOsteopenia/osteoporosisPositive breast cancerRate of adherenceSerious adverse effectsBreast cancer recurrenceMajority of ptsHigher likelihoodElectronic health recordsLocal recurrenceMedian ageLate recurrenceMetastatic recurrenceTumor characteristicsMedication adherenceAbstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Liu M, Robinson P, Yau C, Wallace A, Chien A, Stringer-Reasor E, Nanda R, Yee D, Albain K, Boughey J, Han H, Elias A, Kalinsky K, Clark A, Kemmer K, Isaacs C, Lang J, Lu J, Sanft T, DeMichele A, Hylton N, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Haugen P, Wilson A, Singhrao R, Asare S, Sanil A, Berry D, Esserman L. Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research 2020, 80: p3-09-02-p3-09-02. DOI: 10.1158/1538-7445.sabcs19-p3-09-02.Peer-Reviewed Original ResearchPathological complete responseHER2 negative breast cancerI-SPY 2 TRIALWeeks of paclitaxelNegative breast cancerNeoadjuvant therapyBreast cancerHR-/HER2High-risk stage II/III breast cancerImmune-related adverse eventsPathologic complete response rateRandomized phase 2 trialStage II/III breast cancerHormone-receptorI-SPYEvaluate novel agentsGrade 3 colitisGrade 3 pneumonitisGrade 3 transaminitisPhase 2 trialPhase 3 trialBayesian predictive probability of successNeoadjuvant trialsWeekly paclitaxelComplete responseAbstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer
Onishi N, Li W, Newitt D, Harnish R, Gibbs J, Jones E, Nguyen A, Wilmes L, Joe B, Campbell M, Basu A, van’t Veer L, DiMichele A, Yee D, Berry D, Albain K, Boughey J, Chien A, Clark A, Edmiston K, Elias A, Ellis E, Euhus D, Han H, Isaacs C, Khan Q, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yung R, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, Asare S, Yau J, Yau C, Esserman L, Hylton N. Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer. Cancer Research 2020, 80: pd9-05-pd9-05. DOI: 10.1158/1538-7445.sabcs19-pd9-05.Peer-Reviewed Original ResearchPathological complete responseBackground parenchymal enhancementInferior treatment responseHormone receptor-positive breast cancerPathologic complete response rateReceptor-positive breast cancerPositive breast cancerTreatment responseHR cohortBreast cancerBreast MRINeoadjuvant chemotherapyNon-pCRDegree of BPEI-SPY 2 TRIALQuantitative background parenchymal enhancementStage II/III breast cancerContralateral breast parenchymaPost-NAC MRIHormone receptor statusHR+ breast cancerEffects of chemotherapyEnhanced suppressionStatistically significant associationHR+ cancers